Literature DB >> 21293082

The pharmacological treatment and management of obesity.

Syed Sufyan Hussain1, Stephen Robert Bloom.   

Abstract

Obesity is a pandemic with many complications that increase the societal disease burden and cost of health care, and decrease longevity and quality of life. Currently, 1 in 3 adults in the United States is obese. Physicians must therefore regularly confront obesity and its consequent diseases, and develop strategies for effective treatment and management. This article summarizes current lifestyle modifications, pharmacological treatment, and surgical options for the management of obesity and discusses the benefits, limitations, and risks of each. As insights are gained into the pathophysiology of a gut-brain neurochemical feedback axis governing satiety and feeding behavior, targets for new pharmacotherapies are being developed. In particular, gut hormone analogs are an attractive antiobesity therapy because they appear to lack the adverse effects historically associated with central nervous system-acting agents.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21293082     DOI: 10.3810/pgm.2011.01.2243

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  11 in total

1.  To be or not to be--obese.

Authors:  Stuart Maudsley; Bronwen Martin; Josephine M Egan
Journal:  Endocrinology       Date:  2011-10       Impact factor: 4.736

Review 2.  Managing obesity in adults in primary care.

Authors:  Gilles Plourde; Denis Prud'homme
Journal:  CMAJ       Date:  2012-05-14       Impact factor: 8.262

Review 3.  Potential use of exenatide for the treatment of obesity.

Authors:  Franco Folli; Rodolfo Guardado Mendoza
Journal:  Expert Opin Investig Drugs       Date:  2011-10-24       Impact factor: 6.206

4.  Novel oral anti-obesity agents: new perspectives with lorcaserin?

Authors:  Baptist Gallwitz
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546

5.  Phentermine and topiramate extended release (Qsymia™): first global approval.

Authors:  Fiona Cameron; Glenn Whiteside; Kate McKeage
Journal:  Drugs       Date:  2012-10-22       Impact factor: 9.546

6.  Impact of Bariatric Surgery and Diet Modification on Periodontal Status: A Six Month Cohort Study.

Authors:  Gagan Rajesh Jaiswal; Vijayendra Kumar Jain; Shrikant Vishnu Dhodapkar; Kanteshwari Iranagouda Kumathalli; Rajesh Kumar; Arun Nemawat; Ankita Jain
Journal:  J Clin Diagn Res       Date:  2015-09-01

7.  Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.

Authors:  W Timothy Garvey; Donna H Ryan; Michelle Look; Kishore M Gadde; David B Allison; Craig A Peterson; Michael Schwiers; Wesley W Day; Charles H Bowden
Journal:  Am J Clin Nutr       Date:  2011-12-07       Impact factor: 7.045

Review 8.  The risk of cardiovascular complications with current obesity drugs.

Authors:  Ariana M Chao; Thomas A Wadden; Robert I Berkowitz; Kerry Quigley; Frank Silvestry
Journal:  Expert Opin Drug Saf       Date:  2020-09-09       Impact factor: 4.250

9.  Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.

Authors:  W Timothy Garvey; Donna H Ryan; Robert Henry; Nancy J V Bohannon; Hermann Toplak; Michael Schwiers; Barbara Troupin; Wesley W Day
Journal:  Diabetes Care       Date:  2013-10-08       Impact factor: 19.112

Review 10.  Insights into the role of neuronal glucokinase.

Authors:  Ivan De Backer; Sufyan S Hussain; Stephen R Bloom; James V Gardiner
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-05-17       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.